Lung cancer and malignant pleural mesothelioma

The projects of our research group focus on identifying therapeutic strategies for the treatment of thoracic cancers, including pleural mesothelioma and lung cancer.

In this context, our team investigates thoracic cancers through three main research axes:

i) the development of patient-derived tumour organoids to enable the selection of effective, personalised treatments for each patient ;

ii) the characterisation of the macrophage migration inhibitory factor (MIF) pathway in thoracic cancers, including its role in treatment resistance mechanisms and its potential as a reliable biomarker ;

iii) the identification of novel antitumour compounds, particularly those derived from traditional Chinese medicine.